Skip to main content

Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design

Advances in Therapy volume 33, pages 2069–2081 (2016)Cite this article

Abstract

Introduction

Non-alcoholic steatohepatitis (NASH) is a serious form of non-alcoholic fatty liver disease (NAFLD) that can progress to advanced fibrosis, cirrhosis, and hepatocellular carcinoma. Differentiating between non-alcoholic fatty liver (NAFL) and NASH/advanced fibrosis is an important step in the management of NAFLD. Metabolic syndrome (MS) and its components are important risk factors for NAFLD, and NASH is thought to be the hepatic injury of MS. The prevalence of NASH among NAFLD patients with MS is thought to be high. In China, NAFLD is a relatively new public health concern, and the current prevalence of NASH among Chinese liver biopsy-proven NAFLD patients with and without MS is not known.

Methods

This multicenter, cross-sectional study will investigate the prevalence of NASH in approximately 480 Chinese NAFLD patients. Patients will be eligible for enrollment if they have biopsy-proven NAFLD and if their liver biopsies are available for rereading. For our analysis, patients will be stratified according to the presence/absence of MS, and the prevalence of NASH in the subgroups will be compared. Other possible tests that could indicate a risk of NASH, including transient elastography, ultrasonography, cytokeratin-18, liver function tests, and others, will be studied in an effort to derive a practical, noninvasive predictive model for NASH.

Discussion

Patients with NAFL who have MS may also have a very high risk of developing NASH. The present study will inform about the risk of NASH in Chinese liver biopsy-proven NAFLD patients with and without MS.

Trial Registration

This study registered at http://www.chictr.org.cn (registration number: ChiCTR-OOC-16007902).

Funding

Sanofi (China) Investment Co., Ltd.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–31.

    CAS  Article  PubMed  Google Scholar 

  2. Review Team, LaBrecque DR, Abbas Z, Anania F, Ferenci P, Khan AG, et al. World Gastroenterology Organisation global guidelines: nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol. 2014;48:467–73.

    Google Scholar 

  3. Fan JG, Jia JD, Li YM, et al. Consensus report. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010. J Dig Dis. 2011;12;38–44.

  4. Fan J. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol. 2013;28(Suppl 1):11–7.

    Article  PubMed  Google Scholar 

  5. Li ZZ, Xue P, Chen P, Chen L, Yan SP, Liu LY. Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of published studies. J Gastroenterol Hepatol. 2014;29:42–51.

    CAS  Article  PubMed  Google Scholar 

  6. Fung J, Lee CK, Chan M, Seto WK, Lai CL, Yuen MF, For the Hong Kong Liver Health Census Study Group. High prevalence of non-alcoholic fatty liver disease in the Chinese—results from the Hong Kong liver health census. Liver Int. 2015;35:542–9. doi:10.1111/liv.12619.

  7. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of noninvasive tests for liver disease severity. Ann Med. 2011;43:617–49.

    Article  PubMed  Google Scholar 

  8. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med. 2008;75:721–8.

    Article  PubMed  Google Scholar 

  9. Dam-Larsen S, Franzmann M, Andersen IB, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut. 2004;53:750–5.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. Dam-Larsen S, Becker U, Franzmann MB, Larsen K, Christoffersen P, Bendtsen F. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol. 2009;44:1236–43.

    CAS  Article  PubMed  Google Scholar 

  11. Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7:234–8.

    Article  PubMed  Google Scholar 

  12. Brunt EM, Tiniakos DG. Pathological features of NASH. Front Biosci. 2005;10:1475–84.

    CAS  PubMed  Google Scholar 

  13. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.

    CAS  Article  PubMed  Google Scholar 

  14. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:521–33, viii.

  15. Watanabe S, Hashimoto E, Ikejima K, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hep Res. 2015;45:363–77.

    Article  Google Scholar 

  16. Gill HK, Wu GY. Non-alcoholic fatty liver disease and the metabolic syndrome: effects of weight loss and a review of popular diets. Are low carbohydrate diets the answer? World J Gastroenterol. 2006;12:345–53.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450–5.

    CAS  Article  PubMed  Google Scholar 

  18. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–23.

    Article  PubMed  Google Scholar 

  19. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373–9.

    CAS  Article  PubMed  Google Scholar 

  20. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999;84:1513–7.

    CAS  Article  PubMed  Google Scholar 

  21. Ibrahim M, Singh C, Ganie MA, Alsayari K. NASH: the hepatic injury of metabolic syndrome: a brief update. Int J Health Sci. 2009;3:265–70.

    Google Scholar 

  22. Diehl AM, Clarke J, Brancati F. Insulin resistance syndrome and nonalcoholic fatty liver disease. Endocr Pract. 2003;9(Suppl 2):93–6.

    Article  PubMed  Google Scholar 

  23. Gupte P, Amarapurkar D, Agal S, et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol. 2004;19:854–8.

    Article  PubMed  Google Scholar 

  24. Pratt DS, Kaplan MM. Evaluation of abnormal liver enzyme results in asymptomatic patients. N Engl J Med. 2000;342:1266–71.

    CAS  Article  PubMed  Google Scholar 

  25. Bellentani S, Dalle Grave R, Suppini A, Marchesini G, Fatty Liver Italian Network. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology. 2008;47:746–54.

    Article  PubMed  Google Scholar 

  26. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44:27–33.

    CAS  Article  PubMed  Google Scholar 

  27. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009;50:1072–8.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  28. Chen J, Zhu Y, Zheng Q, Jiang J. Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: a meta-analysis. Hepatol Res. 2014;44:854–62.

    CAS  Article  PubMed  Google Scholar 

  29. Li YM, Fan JG, Wang BY, Lu LG, Shi JP, Niu JQ, et al. Chinese Association for the Study of Liver Disease. Guidelines for the diagnosis and management of alcoholic liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology. 2010;18:167–170). J Dig Dis. 2011;12:45–50.

  30. Byrne CD, Targher G. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate? Diabetologia. 2016;59(6):1141–4.

    CAS  Article  PubMed  Google Scholar 

  31. Tapper EB, Sengupta N, Hunink MGM, Afdhal NH, Lai M. Cost-effective evaluation of nonalcoholic fatty liver disease with NAFLD fibrosis score and vibration controlled transient elastography. Am J Gastroenterol. 2015;110:1298–304.

    Article  PubMed  Google Scholar 

  32. Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007;102:2708–15.

    Article  PubMed  Google Scholar 

  33. Liew P-L, Lee WJ, Lee YC, Wang HH, Wang W, Lin YC. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease. Obesity Surg. 2006;16:1584–93.

    Article  Google Scholar 

  34. Sattar N, Forrest E, Preiss D. Non-alcoholic fatty liver disease. BMJ. 2014;349:g4596.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol. 2004;2:1048–58.

    Article  PubMed  Google Scholar 

  36. van Hoek B, de Rooij BJ, Verspaget HW. Risk factors for infection after liver transplantation. Best Pract Res Clin Gastroenterol. 2012;26:61–72. doi:10.1016/j.bpg.2012.01.004.

    Article  PubMed  Google Scholar 

  37. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52:79–104.

    CAS  Article  PubMed  Google Scholar 

  38. Ratziu V. Pharmacological agents for NASH. Nat Rev Gastroenterol Hepatol. 2013;10:676–85.

    CAS  Article  PubMed  Google Scholar 

  39. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23.

    Article  PubMed  Google Scholar 

  40. Tolman KG, Dalpiaz AS. Treatment of non-alcoholic fatty liver disease. Ther Clin Risk Manag. 2007;3:1153–63.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898–906.

    Article  PubMed  Google Scholar 

  42. Seeff LB, Everson GT, Morgan TR, et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol. 2010;8:877–83.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54:1082–90.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Yoneda M, Yoneda M, Fujita K, et al. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut. 2007;56:1330–1.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Cusi K, Chang Z, Harrison S, et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol. 2014;60:167–74.

    CAS  Article  PubMed  Google Scholar 

  46. Verma S, Jensen D, Hart J, Mohanty SR. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int. 2013;33:1398–405.

    CAS  Article  PubMed  Google Scholar 

  47. Chen Z, Chen L, Dai H, Chen JH, Fang LZ. Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease. J Zhejiang Uni Sci B. 2008;9:616–22.

    CAS  Article  Google Scholar 

  48. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1998;93:44–8.

    CAS  Article  PubMed  Google Scholar 

  49. Bril F, Ortiz-Lopez C, Lomonaco R, et al. Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. Liver Int. 2015;35:2139–46.

    CAS  Article  PubMed  Google Scholar 

  50. Mishra P, Younossi ZM. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol. 2007;102:2716–7.

    Article  PubMed  Google Scholar 

  51. Severson TJ, Besur S, Bonkovsky HL. Genetic factors that affect nonalcoholic fatty liver disease: a systematic clinical review. World J Gastroenterol. 2016;22:6742–56.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Bedossa P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60(2):565–75.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgments

Sponsorship and article processing charges for this study were funded by Sanofi (China) Investment Co., Ltd. We thank Lichuang Men from the Sanofi statistical team for his contributions to our study design. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. Editorial support in the preparation of this publication was provided by Manette Williams (PhD) from Nucleus Shanghai and paid for by Sanofi. The authors, individually and collectively, are responsible for all content and editorial decisions and received no payment from Sanofi directly or indirectly (through a third party) related to the development of this publication.

Disclosures

Xu Zhengjie, Shi Junping, Jia Jidong, and Fan Jian-Gao declare that they have nothing to disclose. Yu Derong is an employee of Sanofi (China) Investment Co., Ltd Shanghai Branch. Zhu Lijuan is an employee of Sanofi (China) Investment Co., Ltd Shanghai Branch.

Compliance with Ethics Guidelines

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent will be waived in view of the retrospective nature of this study and that no sensitive patient data are involved. Amendments to the protocol will take effect only upon approval by the institutional review boards.

Author information

Authors and Affiliations

  1. Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Yangpu District, Shanghai, 200092, China

    Zheng-Jie Xu & Jian-Gao Fan

  2. The Affiliated Hospital of Hangzhou Normal University, 126, Wenzhou Road, Hangzhou, 310015, China

    Jun-Ping Shi

  3. Sanofi (China) Investment Co., Ltd, 19F Tower III Kerry Center, 1228 Middle Yan’an Road, Shanghai, 200040, China

    De-Rong Yu & Li-Juan Zhu

  4. Beijing Friendship Hospital Affiliated to Capital Medical University, 95 Yong’an Road, Western City District, Beijing, 100050, China

    Ji-Dong Jia

Authors
  1. Zheng-Jie Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jun-Ping Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. De-Rong Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Li-Juan Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ji-Dong Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jian-Gao Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Ji-Dong Jia or Jian-Gao Fan.

Additional information

Enhanced content

To view enhanced content for this article go to http://www.medengine.com/Redeem/8AF6F060272CDA41.

Z.-J. Xu and J.-P. Shi are joint first authors.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Xu, ZJ., Shi, JP., Yu, DR. et al. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design. Adv Ther 33, 2069–2081 (2016). https://doi.org/10.1007/s12325-016-0416-4

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-016-0416-4

Keywords

  • Diagnosis
  • Gastroenterology
  • Liver biopsy
  • Metabolic syndrome
  • Non-alcoholic fatty liver disease
  • Non-alcoholic steatohepatitis